Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR405 is a potent and selective small molecule inhibitor of the class III phosphoinositide 3-kinase (PIK3C3, also known as Vps34). By competitively binding to the ATP pocket of Vps34 (Kd: 1.5 nM; IC50: 1.2 nM), SAR405 inhibits its catalytic activity, which disrupts vesicle trafficking from late endosomes to lysosomes and prevents autophagy[1][3][5][7]. SAR405 also fully inhibits autophagy induced by starvation or MTOR (mechanistic target of rapamycin) inhibition and has shown synergy with MTOR inhibition in reducing cell proliferation in tumor cell models[1][5][7]. Its high selectivity profile makes it a unique research tool for dissecting autophagy mechanisms[5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SAR405.